Rigel Pharmaceuticals (RIGL) News Today

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) appears to be under pressure after a series of analyst estimate cuts and a slightly lower price target.

• Positive Sentiment: Citigroup kept a buy rating on Rigel Pharmaceuticals while trimming its price target only modestly to $69 from $71, which still implies significant upside from current levels. Citigroup price target update
• Neutral Sentiment: HC Wainwright continued to model strong profitability for Rigel, but now expects FY2026 EPS of $4.01, FY2027 EPS of $3.40, and FY2028 EPS of $3.91. The firm’s estimates remain above the current consensus for the year, but they were cut from prior forecasts. HC Wainwright estimate revisions
• Negative Sentiment: HC Wainwright lowered near-term earnings expectations for Rigel, cutting Q2 2026 EPS to $1.11, Q3 2026 EPS to $1.18, and Q4 2026 EPS to $1.26. Lower forecasted earnings can weigh on investor sentiment and help explain the stock’s weakness. HC Wainwright quarterly estimate cuts

Overall, RIGL is likely moving lower because analysts trimmed earnings estimates across multiple periods, signaling slightly less confidence in the company’s near-term and long-term profit trajectory. The downgrade in expectations appears to outweigh the still-bullish ratings and price targets.